# US 2013/0252832 A1 · KRAS Variant and Tumor Biology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252832 A1
- Document ID: US20130252832A1
- Status: Published application
- Kind: A1
- Application number: 13/427,523
- Filed: 2012-03-22
- Published: 2013-09-26
- Earliest claimed: 2012-03-22
- Assignees: Yale University
- Inventors: Joanne B. Weidhaas
- Web page: https://patentgrep.com/patent/US20130252832A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant.

## Claims

### Claim 1

A method of identifying a subject or patient at risk for developing an estrogen receptor (ER) and progesterone receptor (PR) negative (ER/PR negative) breast cancer, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates an increased risk of developing the ER/PR negative breast cancer in the subject.

### Claim 2

A method of predicting the onset of developing an estrogen receptor (ER) and progesterone receptor (PR) negative (ER/PR negative) breast cancer in a subject or patient at risk for developing breast cancer, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates an earlier onset of developing the ER/PR negative breast cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ER/PR negative breast cancer is also negative for HER2, and therefore, is a triple negative breast cancer (TNBC).

### Claim 4 (depends on 3)

The method of claim 3, wherein the triple negative breast cancer (TNBC) is a basal or luminal tumor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the triple negative breast cancer (TNBC) is a basal tumor that expresses a transcript or protein encoded by the epidermal growth factor receptor (EGFR) or the cytokeratin 5/6 (CK5/6) gene.

### Claim 6 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein the breast cancer is further characterized by low or negative expression of the breast cancer 1 (BRCA1) gene.

### Claim 7 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein the subject or patient is pre-menopausal.

### Claim 8 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein the subject or patient is 51 years of age or younger.

### Claim 9

A method of prognosing a subject or patient with epithelial ovarian cancer (EOC), comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a decreased survival rate when compared to a control.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject or patient is post-menopausal, 52 years of age, or at least 52 years of age.

### Claim 11 (depends on 9)

The method of claim 9, wherein the control does not carry the mutation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the survival rate is overall survival, five-year survival or one-year survival.

### Claim 13

A method of predicting the response of an epithelial ovarian cancer (EOC) cell to a platinum-based chemotherapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, wherein the presence of the mutation indicates a resistance to platinum-based chemotherapy.

### Claim 14 (depends on 13)

The method of claim 13, wherein the EOC cell is evaluated in vitro or ex vivo.

### Claim 15 (depends on 14)

The method of claim 14, wherein the EOC cell is evaluated ex vivo from a subject who is post-menopausal, 52 years of age, or at least 52 years of age.

### Claim 16 (depends on 14)

The method of claim 14, wherein the EOC cell is evaluated in vitro and wherein the EOC cell is isolated, reproduced, or derived from the BG1, CAOV3, or IGR-OV1 cell line.

### Claim 17 (depends on 13)

The method of claim 13, wherein the platinum-based chemotherapy is carboplatin or paclitaxel.

### Claim 18 (depends on 13)

The method of claim 13, wherein the platinum-based chemotherapy is an adjuvant therapy.

### Claim 19

A method of prognosing a subject or patient with colorectal cancer (CRC), comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, wherein the presence of the mutation indicates a increased survival rate when compared to a control.

### Claim 20 (depends on 19)

The method of claim 19, wherein the detecting step further comprises microsatellite-instability (MSI) analysis.

### Claim 21 (depends on 19)

The method of claim 19, wherein the colorectal cancer (CRC) is early stage CRC.

### Claim 22 (depends on 19)

The method of claim 19, wherein the colorectal cancer (CRC) is stage 1 or 2 CRC.

### Claim 23 (depends on 19)

The method of claim 19, wherein the control does not carry the KRAS-variant.

### Claim 24 (depends on 23)

The method of claim 23, wherein the control has a second mutation in the KRAS gene.

### Claim 25 (depends on 19)

The method of claim 19, wherein the subject or patient has a second mutation in the KRAS gene.

### Claim 26 (depends on 19)

The method of claim 19, wherein the subject or control carries one or more mutations in the BRAF gene.

### Claim 27 (depends on 19)

The method of claim 19, wherein the subject or control has a hypermethylated RASSF1A promoter.

### Claim 28 (depends on 19)

The method of claim 19, wherein the survival rate is overall survival, five-year survival or one-year survival.

### Claim 29

A method of predicting the response of a cancer cell to a monoclonal antibody monotherapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a sensitivity to monoclonal antibody monotherapy.

### Claim 30 (depends on 29)

The method of claim 29, wherein the cancer cell is a colorectal cancer (CRC) cell.

### Claim 31 (depends on 29)

The method of claim 29, wherein the cancer cell is evaluated in vitro or ex vivo.

### Claim 32 (depends on 29)

The method of claim 29, wherein the monoclonal antibody monotherapy is Cetuximab.

### Claim 33

A method of predicting the response of a cancer cell to the combination of a chemotherapy and monoclonal antibody therapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a resistance to the combination.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cancer cell is a colorectal cancer (CRC) cell.

### Claim 35 (depends on 33)

The method of claim 33, wherein the cancer cell is evaluated in vitro or ex vivo.

### Claim 36 (depends on 33)

The method of claim 33, wherein the monoclonal antibody monotherapy is Cetuximab.

### Claim 37 (depends on 33)

The method of claim 33, wherein the chemotherapy is a cytotoxic agent.

### Claim 38 (depends on 37)

The method of claim 37, wherein the cytotoxic agent is irinotecan.

### Claim 39

A method of predicting the an increased risk of vascularization of a tumor, comprising
(a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
(b) determining the expression level of a miRNA selected from the group consisting of miR-23 and miR-27 in a second patient sample,
wherein the presence of the mutation in (a) and an increase in the expression level of a miRNA in (b) compared to a control indicates transcriptional silencing of an anti-angiogenic gene, thereby predicting the an increased risk of vascularization of the tumor.

### Claim 40 (depends on 39)

The method of claim 39, wherein the anti-angiogenic gene is Sprouty2 or Sema 6A.

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, wherein the tumor comprises a cancer cell derived from a(n) AIDS-related cancer, breast cancer, cancer of the digestive/gastrointestinal tract, anal cancer, appendix cancer, bile duct cancer, colon cancer, colorectal cancer, esophageal cancer, gallbladder cancer, islet cell tumors, pancreatic neuroendocrine tumors, liver cancer, pancreatic cancer, rectal cancer, small intestine cancer, stomach (gastric) cancer, endocrine system cancer, adrenocortical carcinoma, parathyroid cancer, pheochromocytoma, pituitary tumor, thyroid cancer, eye cancer, intraocular melanoma, retinoblastoma, bladder cancer, kidney (renal cell) cancer, penile cancer, prostate cancer, transitional cell renal pelvis and ureter cancer, testicular cancer, urethral cancer, Wilms' tumor, other childhood kidney tumors, germ cell cancer, central nervous system cancer, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gynecologic cancer, cervical cancer, endometrial cancer, gestational trophoblastic tumor, ovarian epithelial cancer, uterine sarcoma, vaginal cancer, vulvar cancer, head and neck cancer, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic squamous neck cancer with occult primary, mouth cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal cavity cancer, pharyngeal cancer, salivary gland cancer, throat cancer, musculoskeletal cancer, bone cancer, Ewing's sarcoma, gastrointestinal stromal tumors (GIST), osteosarcoma, malignant fibrous histiocytoma of bone, rhabdomyosarcoma, soft tissue sarcoma, uterine sarcoma, neurologic cancer, brain tumor, astrocytoma, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumor, craniopharyngioma, ependymoma, medulloblastoma, spinal cord tumor, supratentorial primitive neuroectodermal tumors and pineoblastoma, neuroblastoma, respiratory cancer, thoracic cancer, non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, thymoma, thymic carcinoma, skin cancer, Kaposi's sarcoma, melanoma, or Merkel cell carcinoma.

### Claim 42 (depends on 39, 41)

The method of claim 39 or 41, wherein the tumor is metastic.

### Claim 43

A method of predicting an increased survival or proliferation of a cancer cell under hypoxic conditions, comprising
(a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
(b) determining the expression level of a miR-210 miRNA in a second patient sample,
wherein the presence of the mutation in (a) and an increase in the expression level of the miRNA in (b) compared to a control predicts an increased survival or proliferation of the cancer cell under hypoxic conditions.

### Claim 44 (depends on 43)

The method of claim 43, wherein the cancer cell is derived from a(n) AIDS-related cancer, breast cancer, cancer of the digestive/gastrointestinal tract, anal cancer, appendix cancer, bile duct cancer, colon cancer, colorectal cancer, esophageal cancer, gallbladder cancer, islet cell tumors, pancreatic neuroendocrine tumors, liver cancer, pancreatic cancer, rectal cancer, small intestine cancer, stomach (gastric) cancer, endocrine system cancer, adrenocortical carcinoma, parathyroid cancer, pheochromocytoma, pituitary tumor, thyroid cancer, eye cancer, intraocular melanoma, retinoblastoma, bladder cancer, kidney (renal cell) cancer, penile cancer, prostate cancer, transitional cell renal pelvis and ureter cancer, testicular cancer, urethral cancer, Wilms' tumor, other childhood kidney tumors, germ cell cancer, central nervous system cancer, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gynecologic cancer, cervical cancer, endometrial cancer, gestational trophoblastic tumor, ovarian epithelial cancer, uterine sarcoma, vaginal cancer, vulvar cancer, head and neck cancer, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic squamous neck cancer with occult primary, mouth cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal cavity cancer, pharyngeal cancer, salivary gland cancer, throat cancer, musculoskeletal cancer, bone cancer, Ewing's sarcoma, gastrointestinal stromal tumors (GIST), osteosarcoma, malignant fibrous histiocytoma of bone, rhabdomyosarcoma, soft tissue sarcoma, uterine sarcoma, neurologic cancer, brain tumor, astrocytoma, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumor, craniopharyngioma, ependymoma, medulloblastoma, spinal cord tumor, supratentorial primitive neuroectodermal tumors and pineoblastoma, neuroblastoma, respiratory cancer, thoracic cancer, non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, thymoma, thymic carcinoma, skin cancer, Kaposi's sarcoma, melanoma, or Merkel cell carcinoma.

### Claim 45

A method of predicting an increased survival or proliferation of a cancer cell, comprising
(a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
(b) determining the methylation status of a promoter of a tumor suppressor gene in a second patient sample,
wherein the presence of the mutation in (a) and an increase in the methylation of a promoter (b) compared to a control predicts an increased survival or proliferation of the cancer cell.

### Claim 46 (depends on 45)

The method of claim 45, wherein tumor suppressor gene is Notch1.

### Claim 47 (depends on 45)

The method of claim 45, wherein the cancer cell is derived from a(n) AIDS-related cancer, breast cancer, cancer of the digestive/gastrointestinal tract, anal cancer, appendix cancer, bile duct cancer, colon cancer, colorectal cancer, esophageal cancer, gallbladder cancer, islet cell tumors, pancreatic neuroendocrine tumors, liver cancer, pancreatic cancer, rectal cancer, small intestine cancer, stomach (gastric) cancer, endocrine system cancer, adrenocortical carcinoma, parathyroid cancer, pheochromocytoma, pituitary tumor, thyroid cancer, eye cancer, intraocular melanoma, retinoblastoma, bladder cancer, kidney (renal cell) cancer, penile cancer, prostate cancer, transitional cell renal pelvis and ureter cancer, testicular cancer, urethral cancer, Wilms' tumor, other childhood kidney tumors, germ cell cancer, central nervous system cancer, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gynecologic cancer, cervical cancer, endometrial cancer, gestational trophoblastic tumor, ovarian epithelial cancer, uterine sarcoma, vaginal cancer, vulvar cancer, head and neck cancer, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic squamous neck cancer with occult primary, mouth cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal cavity cancer, pharyngeal cancer, salivary gland cancer, throat cancer, musculoskeletal cancer, bone cancer, Ewing's sarcoma, gastrointestinal stromal tumors (GIST), osteosarcoma, malignant fibrous histiocytoma of bone, rhabdomyosarcoma, soft tissue sarcoma, uterine sarcoma, neurologic cancer, brain tumor, astrocytoma, brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, central nervous system germ cell tumor, craniopharyngioma, ependymoma, medulloblastoma, spinal cord tumor, supratentorial primitive neuroectodermal tumors and pineoblastoma, neuroblastoma, respiratory cancer, thoracic cancer, non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, thymoma, thymic carcinoma, skin cancer, Kaposi's sarcoma, melanoma, or Merkel cell carcinoma.

### Claim 48 (depends on 45)

The method of claim 45, wherein survival comprises maintaining tumorigenic potential.

### Claim 49 (depends on 45, 48)

The method of claim 45 or 48, wherein the cancer cell is a cancer stem cell.
